ECC4703 for non-alcoholic fatty liver disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 15 Dec 2025: Trial started, NCT07288138
  2. 17 Dec 2025: Trial registered, NCT07288138

The trials

NCT07288138: A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)

State
Under way
Phase
Phase 2
People
160 planned
Started
15 Dec 2025
Primary completion
15 Sep 2027
Arms
ECC4703 Low Dose, ECC4703 High Dose
Results
None posted
  1. 15 Dec 2025: Trial started
  2. 17 Dec 2025: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.